These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35535211)

  • 1. Efficacy and Safety of Low-Dose Rituximab in Anti-MuSK Myasthenia Gravis Patients: A Retrospective Study.
    Meng X; Zeng Z; Wang Y; Guo S; Wang C; Wang B; Guo S
    Neuropsychiatr Dis Treat; 2022; 18():953-964. PubMed ID: 35535211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
    Hehir MK; Hobson-Webb LD; Benatar M; Barnett C; Silvestri NJ; Howard JF; Howard D; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; LaBoy SM; Fellman MA; Greene SM; Pasnoor M; Burns TM
    Neurology; 2017 Sep; 89(10):1069-1077. PubMed ID: 28801338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
    Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
    Front Immunol; 2020; 11():613. PubMed ID: 32431692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of rituximab on prognosis in myasthenia gravis: A single-center experience from Turkey].
    Göl MF; Kara F; Boz M; Mutlu A; Karakullukçu S; Boz C
    Ideggyogy Sz; 2022 Sep; 75(9-10):351-359. PubMed ID: 36218113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in Myasthenia Gravis- Experience from a Low- and Middle-Income Country (LMIC) Setting.
    Shivaram S; Nagappa M; Varghese N; Seshagiri DV; Duble S; Siddappa SA; Hesarur N; Sinha S; Taly AB
    Neurol India; 2022; 70(5):1931-1941. PubMed ID: 36352590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study.
    Dos Santos A; Noury JB; Genestet S; Nadaj-Pakleza A; Cassereau J; Baron C; Videt D; Michel L; Pereon Y; Wiertlewski S; Magot A
    Eur J Neurol; 2020 Nov; 27(11):2277-2285. PubMed ID: 32526053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.
    Topakian R; Zimprich F; Iglseder S; Embacher N; Guger M; Stieglbauer K; Langenscheidt D; Rath J; Quasthoff S; Simschitz P; Wanschitz J; Windisch D; Müller P; Oel D; Schustereder G; Einsiedler S; Eggers C; Löscher W
    J Neurol; 2019 Mar; 266(3):699-706. PubMed ID: 30649616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study.
    Singh N; Goyal V
    J Neurol; 2019 Jul; 266(7):1596-1600. PubMed ID: 30919039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study.
    Zhao S; Zhang K; Ren K; Lu J; Ma C; Zhao C; Li Z; Guo J
    BMC Neurol; 2021 Nov; 21(1):428. PubMed ID: 34732168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
    Du Y; Li C; Hao YF; Zhao C; Yan Q; Yao D; Li L; Zhang W
    J Neurol; 2022 Aug; 269(8):4229-4240. PubMed ID: 35243555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study.
    Litchman T; Roy B; Kumar A; Sharma A; Njike V; Nowak RJ
    J Neurol Sci; 2020 Apr; 411():116690. PubMed ID: 32028072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients.
    Afanasiev V; Demeret S; Bolgert F; Eymard B; Laforêt P; Benveniste O
    Neuromuscul Disord; 2017 Mar; 27(3):251-258. PubMed ID: 28082209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
    Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
    J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.
    Li T; Zhang GQ; Li Y; Dong SA; Wang N; Yi M; Qi Y; Zhai H; Yang L; Shi FD; Yang CS
    J Clin Neurosci; 2021 Mar; 85():6-12. PubMed ID: 33581791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.
    Clifford KM; Hobson-Webb LD; Benatar M; Burns TM; Barnett C; Silvestri NJ; Howard JF; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; Laboy SM; Fellman MA; Howard DB; Kolb NA; Greene SM; Pasnoor M; Dimachkie MM; Barohn RJ; Hehir MK
    Muscle Nerve; 2019 Apr; 59(4):404-410. PubMed ID: 30575980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia.
    Caballero-Ávila M; Álvarez-Velasco R; Moga E; Rojas-Garcia R; Turon-Sans J; Querol L; Olivé M; Reyes-Leiva D; Illa I; Gallardo E; Cortés-Vicente E
    Neuromuscul Disord; 2022 Aug; 32(8):664-671. PubMed ID: 35811274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis.
    Bastakoti S; Kunwar S; Poudel S; Quinonez J; Bista S; Singh N; Jha V; Ruxmohan S; Paesani S; Cueva W; Michel J
    Cureus; 2021 Nov; 13(11):e19416. PubMed ID: 34909332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rituximab for the treatment of generalised myasthenia gravis: experience in clinical practice].
    Martínez-Monte E; Gascón-Giménez F; Domínguez-Morán JA; Láinez-Andres JM
    Rev Neurol; 2021 Nov; 73(12):416-420. PubMed ID: 34877644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab treatment of myasthenia gravis: A systematic review.
    Tandan R; Hehir MK; Waheed W; Howard DB
    Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation between clinical manifestation, prognosis and antibody in anti-muscle-specific tyrosine kinase antibody positive myasthenia gravis].
    Tan Y; Zhu L; Huang YY; Shi JY; Li J; Li K; Guan YZ; Cui LY
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(31):2433-2437. PubMed ID: 34399555
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.